These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 18775103)

  • 1. A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.
    Mel JR; Salar A; Rodríguez CA; Alegre A; González A; Cassinello J; Montesinos J; Gasquet JA; Sánchez J; Saigí E;
    Curr Med Res Opin; 2008 Oct; 24(10):2931-42. PubMed ID: 18775103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy.
    Esquerdo G; Doménech M; López P; Pedro C; Villadiego K; Constenla M; Sánchez-Rovira P; Gasquet JA; Rodríguez CA;
    Tumori; 2014; 100(2):225-31. PubMed ID: 24852870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level.
    Esquerdo G; Llorca C; Cervera JM; Orts D; Juárez A; Carrato A
    Clin Transl Oncol; 2011 May; 13(5):341-7. PubMed ID: 21596663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.
    Canon JL; Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Legg J; Pujol B; Bridges K
    Med Oncol; 2012 Sep; 29(3):2291-9. PubMed ID: 22081263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
    Roger SD; Kolmakova E; Fung M; Malecki R; Vinhas J; Dellanna F; Thomas M; Manamley N; Ferenczi S
    Nephrology (Carlton); 2014 May; 19(5):266-74. PubMed ID: 24506498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
    Boccia R; Lillie T; Tomita D; Balducci L
    Oncologist; 2007 May; 12(5):584-93. PubMed ID: 17522247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O; Garassino M; Sacchetta S; Caristo R; Zivi A; Cerbone L; Mancuso A
    Anticancer Res; 2008; 28(3B):1767-71. PubMed ID: 18630457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, observational study describing the haematological response in patients undergoing chemotherapy treated by tri-weekly darbepoetin alfa for anaemia.
    Ray-Coquard I; Laplaige P; Vey N; Asselain B; Urbieta M
    Curr Med Res Opin; 2010 Nov; 26(11):2653-60. PubMed ID: 20932223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL.
    Pirker R; Hedenus M; Vansteenkiste J; Hernandez E; Belton L; Terwey JH
    Clin Ther; 2016 Jan; 38(1):122-135.e6. PubMed ID: 26730453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study.
    Kotasek D; Steger G; Faught W; Underhill C; Poulsen E; Colowick AB; Rossi G; Mackey J;
    Eur J Cancer; 2003 Sep; 39(14):2026-34. PubMed ID: 12957457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
    J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
    Canaud B; Mingardi G; Braun J; Aljama P; Kerr PG; Locatelli F; Villa G; Van Vlem B; McMahon AW; Kerloëguen C; Beyer U;
    Nephrol Dial Transplant; 2008 Nov; 23(11):3654-61. PubMed ID: 18586762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
    Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
    J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study.
    Aerts JG; Swieboda-Sadlej A; Karanikiotis C; Labourey JL; Galid A; Wheeler T; Pujol B; Van Belle S
    Curr Med Res Opin; 2012 Jul; 28(7):1089-99. PubMed ID: 22642866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R; Malik IA; Raja V; Kahanic S; Liu R; Lillie T; Tomita D; Clowney B; Silberstein P
    Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
    Hudis CA; Vogel CL; Gralow JR; Williams D;
    Clin Breast Cancer; 2005 Jun; 6(2):132-42. PubMed ID: 16001991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
    Schwartzberg L; Burkes R; Mirtsching B; Rearden T; Silberstein P; Yee L; Inamoto A; Lillie T
    BMC Cancer; 2010 Oct; 10():581. PubMed ID: 20973982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
    Henry DH
    Drugs; 2007; 67(2):175-94. PubMed ID: 17284083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective cohort study on the impact of darbepoetin alfa on quality of life in daily practice following anemia treatment guideline revisions.
    Steinmetz T; Kindler M; Lange O; Vehling-Kaiser U; Kuhn A; Hellebrand E
    Curr Med Res Opin; 2014 Sep; 30(9):1813-20. PubMed ID: 24849527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies.
    Hedenus M; Hansen S; Taylor K; Arthur C; Emmerich B; Dewey C; Watson D; Rossi G; Osterborg A;
    Br J Haematol; 2002 Oct; 119(1):79-86. PubMed ID: 12358906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.